The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials
Open Access
- 1 November 2014
- journal article
- review article
- Published by Elsevier BV in Neuron
- Vol. 84 (3), 608-622
- https://doi.org/10.1016/j.neuron.2014.10.038
Abstract
No abstract availableKeywords
This publication has 141 references indexed in Scilit:
- An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer diseaseAnnals of Neurology, 2011
- Amyloid‐β associated volume loss occurs only in the presence of phospho‐tauAnnals of Neurology, 2011
- Hippocampal hyperactivation in presymptomatic familial Alzheimer's diseaseAnnals of Neurology, 2010
- Amyloid‐β associated cortical thinning in clinically normal elderlyAnnals of Neurology, 2010
- Pathological 43-kDa Transactivation Response DNA-Binding Protein in Older Adults With and Without Severe Mental IllnessArchives of Neurology, 2010
- Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly PeopleArchives of Neurology, 2010
- Cognition, reserve, and amyloid deposition in normal agingAnnals of Neurology, 2010
- Cognitive Decline and Brain Volume Loss as Signatures of Cerebral Amyloid-β Peptide Deposition Identified With Pittsburgh Compound BArchives of Neurology, 2009
- Cerebrospinal fluid tau and ptau 181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's diseaseEMBO Molecular Medicine, 2009
- Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the ElderlyArchives of Neurology, 2008